ACH-IMATINIB TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

IMATINIB (IMATINIB MESYLATE)

Inapatikana kutoka:

ACCORD HEALTHCARE INC

ATC kanuni:

L01EA01

INN (Jina la Kimataifa):

IMATINIB

Kipimo:

400MG

Dawa fomu:

TABLET

Tungo:

IMATINIB (IMATINIB MESYLATE) 400MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

ANTINEOPLASTIC AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0145503003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2019-07-29

Tabia za bidhaa

_ACH-IMATINIB (imatinib mesylate tablets) _
_Page 1 of 78 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-IMATINIB
Imatinib Mesylate Tablets
Tablets, 100 mg and 400 mg imatinib (as imatinib mesylate), Oral
Protein kinase inhibitor
(ATC code: L01EA01)
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Initial Authorization:
July 29, 2019
Date of Revision:
November 22, 2023
Submission Control Number: 278120
_ACH-IMATINIB (imatinib mesylate tablets) _
_Page 2 of 78 _
RECENT MAJOR LABEL CHANGES
Section 7 Warnings and Precautions, Musculoskeletal
12/2022
Section 1 INDICATIONS
11/2023
Section 1 INDICATIONS, 1.2 Geriatrics
11/2023
Section 3 SERIOUS WARNINGS AND PRECAUTIONS BOX
11/2023
Section 4.2 Recommended Dose and Dosage Adjustment
11/2023
Section 7 WARNINGS AND PRECAUTIONS, Hemorrhage
11/2023
Section 7 WARNINGS AND PRECAUTIONS,
Hepatic/biliary/Pancreatic
11/2023
Section 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
11/2023
Section 8.2 Clinical Trial Adverse Reactions
11/2023
Section 8.4 Abnormal laboratory Findings: Hematologic,
Clinical Chemistry and Other Quantitative Data
11/2023
Section 10.1 Mechanism of Action
11/2023
Section 14 CLINICAL TRIALS, 14.1 Clinical Trials by Indication
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................5
1.2
Geriatrics
.......................